HCM
MREO

Hall Capital Management’s Mereo BioPharma MREO Stock Holding History

Hall Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,000
Closed -$11K – 92
2022
Q2 		$11K Buy
+10,000
New +$7.75K 0.01% 90

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Hall Capital Management's MREO Position: Q3 2022 in Review

Hall Capital Management sold out of Mereo BioPharma (MREO) in Q3 2022, closing a stake of 10,000 shares — an estimated $11K sold.

Hall Capital Management first reported a position in MREO in Q2 2022 and held it in 1 quarter. The position peaked at $11K in Q2 2022. 63 funds tracked by Wall St. Rank hold MREO as of Q3 2022.

  • Hall Capital Management reported no remaining Mereo BioPharma position as of Q3 2022 after selling out during the quarter.
  • Hall Capital Management sold 10,000 Mereo BioPharma shares in Q3 2022, an estimated $11K.
  • Hall Capital Management first reported a position in Mereo BioPharma in Q2 2022 and held it in 1 quarter.
  • Hall Capital Management's Mereo BioPharma position peaked at $11K in Q2 2022.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2022.

Based on Hall Capital Management's 13F filing for Q3 2022, filed 19 Oct 2022.